Mohammad Abavisani

Mohammad Abavisani

Auto-generated profile, based on publicly available information

Mohammad Abavisani

Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Letters in Applied Microbiology
Verified
Journal Article
Open access
PDF file
MAMohammad Abavisani
Mohammad Abavisani
NBNarjess Bostanghadiri
Narjess Bostanghadiri
HGHossein Ghahramanpour
Hossein Ghahramanpour
MKMansoor Kodori
Mansoor Kodori
FAFariba Akrami
Fariba Akrami
MRMohsen Rastegari-Pouyani
Mohsen Rastegari-Pouyani
Multidrug-resistant (MDR) Escherichia coli strains have rapidly increased worldwide, and effective antibiotic therapeutic options are becoming more restricted. As a polymyxin antibiotic, colistin has a long history of usage, and it is used as a final line of treatment for severe infections by Gram-negative bacteria (GNB) with high-level resistance. However, its application has been challenged by the emergence of E. coli colistin resistance. Hence, determining the mechanism that confers colistin resistance is crucial for monitoring and controlling the dissemination of colistin-resistant E. coli strains. This comprehensive review summarizes colistin resistance mechanisms in E. coli strains and concentrates on the history, mode of action, and therapeutic implications of colistin. We have mainly focused on the fundamental mechanisms of colistin resistance that are mediated by chromosomal or plasmid elements and discussed major mutations in the two-component systems (TCSs) genes and plasmids that transmit the mcr resistant genes in E. coli strains.

1 January 2024 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
MAMohammad Abavisani
Mohammad Abavisani
BABahareh Ansari
Bahareh Ansari
NENegar Ebadpour
Negar Ebadpour
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar
Abavisani M, et al. Clin Exp Vaccine Res. 2024 Oct;13(4):271-300. https://doi.org/10.7774/cevr.2024.13.4.271